This SIG reveals recent progress made in liver fibrosis related to NASH, including new molecular mechanisms and translational aspects of NASH-mediated fibrosis and cirrhosis, and translation of laboratory findings into humans. Speakers will cover significant new information about the potential role of hepatocytes, crosstalk with non-parenchymal cells in NASH-fibrosis, and potential non-invasive biomarkers and treatments of patients with NASH-fibrosis.

Explore critical, clinically relevant topics related to basic mechanisms of hepatotoxicity at this SIG. Each talk begins with a patient case presented by a trainee. Discussion topics include how the hepatocyte responds to stress, including antibiotics and other medications; the genetic and epigenetic basis of drug-induced liver injury; and the interplay of adaptive immunity and liver injury.

This program will summarize key concepts in U.S. and global strategies to achieve hepatitis C elimination. Experts will address topics such as new universal screening recommendations, novel paradigms for care delivery beyond the specialty clinic, global strategies for microelimination, treatment as prevention in persons who inject drugs (PWID), and the latest updates on HCV vaccine development.

Explore timely topics in liver disease in a lively debate format as pediatric and adult/general hepatology trainees and practicing hepatologists tackle important, often controversial issues. Debaters will gain skills in critical thinking, balanced argumentation and factual examination of each issue's pros and cons. Debaters, judges and audience members will grapple with opposing scientific, societal, individual and financial viewpoints on current clinical concerns. 

The Ohio State Wexner Medical Center vs Hospital University of Pennsylvania 

At this year's Thomas E. Starzl lecture, an expert in the field will discuss the most recent developments and controversies concerning living donor liver transplantation. The lecture will encompass topics like the current need for living organ donors, and the balance of donor and recipient risks with benefits for both parties in this life-saving procedure.

This engaging session will explore hot topics in the management of liver cancer, including talks on hepatobiliary neoplasia and liver transplant. The program's first segment will address advancements in research on the pathogenesis and surgical management of liver cancer, while the second half provides analysis of the newest advances in the systemic management of both iCCA and HCC.

Véronique Loustaud‐Ratti, Alicia Anneraud, Paul Carrier, Marilyne Debette‐Gratien, Anne De Muret, Mattias Tallegas, Hélène Barraud, Louise Barbier, Ephrem Salamé – 13 November 2020

Xuemei Gu, Rui Sun, Liang Chen, Shenghui Chu, Mark A. Doll, Xiaohong Li, Wenke Feng, Leah Siskind, Craig J. McClain, Zhongbin Deng – 13 November 2020

Mark R. Pedersen, Garrett Greenan, Sumant Arora, Arvind R. Murali, Marlyn J. Mayo – 13 November 2020 – After liver transplantation (LT), the role of ursodeoxycholic acid (UDCA) is not well characterized. We examine the effect of UDCA after LT in the prophylaxis of biliary complications (BCs) in all‐comers for LT and the prevention of recurrent primary biliary cholangitis (rPBC) in patients transplanted for PBC.

Krystal L. Karunungan, Yas Sanaiha, Roland A. Hernandez, Holly Wilhalme, Sarah Rudasill, Joseph Hadaya, Joseph DiNorcia, Peyman Benharash – 13 November 2020 – Although socioeconomic disparities persist both pre‐ and post‐transplantation, the impact of payer status has not been studied at the national level. We examined the association between public insurance coverage and waitlist outcomes among candidates listed for liver transplantation (LT) in the United States. All adults (age ≥18 years) listed for LT between 2002 and 2018 in the United Network for Organ Sharing database were included.